Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.

J Immunother Cancer · 2021 · PMC8287616 · PMID 34272304

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

34 35 The patients with strongly inhibiting ligand HLA-Bw4 I80 and KIR3DL1 combinations showed a trend towards improved PFS compared with patients carrying weakly inhibiting KIR3DL1+HLA-Bw4 T80+ combination (MST=11.99 vs 5.98 months, HR=1.81 (95% CI 0.71 to 4.60), p=0.4); however, this difference was not significant ( online supplemental figure 6C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.